[1] |
LI M, DAL MASO L, VACCARELLA S. Global trends in thyroid cancer incidence and the impact of overdiagnosis[J]. Lancet Diabetes Endocrinol, 2020, 8(6):468-470.
DOI
URL
|
[2] |
HIRSCH D, LEVY S, TSVETOV G, et al. Long-term outcomes and prognostic factors in patients with differentiated thyroid cancer and distant metastases[J]. Endocr Pract, 2017, 23(10):1193-1200.
DOI
PMID
|
[3] |
WANG W, CHANG J, JIA B, et al. The blood biomarkers of thyroid cancer[J]. Cancer Manag Res, 2020, 12:5431-5438.
DOI
PMID
|
[4] |
UENO N, LING N, YING S Y, et al. Isolation and partial characterization of follistatin:a single-chain Mr 35 000 monomeric protein that inhibits the release of follicle-stimulating hormone[J]. Proc Natl Acad Sci U S A, 1987, 84(23):8282-8286.
DOI
URL
|
[5] |
SEPPORTA M V, TUMMINELLO F M, FLANDINA C, et al. Follistatin as potential therapeutic target in prostate cancer[J]. Target Oncol, 2013, 8(4):215-223.
DOI
PMID
|
[6] |
HODA M A, ROZSAS A, LANG E, et al. High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma[J]. Oncotarget, 2016, 7(12):13388-13399.
DOI
PMID
|
[7] |
CHOI K, JANG H Y, AHN J M, et al. The association of the serum levels of myostatin,follistatin,and interleukin-6 with sarcopenia,and their impacts on survival in patients with hepatocellular carcinoma[J]. Clin Mol Hepatol, 2020, 26(4):492-505.
DOI
URL
|
[8] |
TUMMINELLO F M, BADALAMENTI G, FULFARO F, et al. Serum follistatin in patients with prostate cancer metastatic to the bone[J]. Clin Exp Metastasis, 2010, 27(8):549-555.
DOI
URL
|
[9] |
REN P, CHEN F F, LIU H Y, et al. High serum levels of follistatin in patients with ovarian cancer[J]. J Int Med Res, 2012, 40(3):877-886.
PMID
|
[10] |
PANAGIOTOU G, GHALY W, UPADHYAY J, et al. Serum follistatin is increased in thyroid cancer and is associated with adverse tumor characteristics in humans[J]. J Clin Endocrinol Metab, 2021, 106(5):e2137-e2150.
DOI
PMID
|
[11] |
JANIK S, BEKOS C, HACKER P, et al. Follistatin impacts tumor angiogenesis and outcome in thymic epithelial tumors[J]. Sci Rep, 2019, 9(1):17359.
DOI
PMID
|
[12] |
KRNETA J, KROLL J, ALVES F, et al. Dissociation of angiogenesis and tumorigenesis in follistatin- and activin-expressing tumors[J]. Cancer Res, 2006, 66(11):5686-5695.
PMID
|
[13] |
GUO K, WANG Z. Risk factors influencing the recurrence of papillary thyroid carcinoma:a systematic review and meta-analysis[J]. Int J Clin Exp Pathol, 2014, 7(9):5393-5403.
|
[14] |
LE BRAS G F, LOOMANS H A, TAYLOR C J, et al. Activin A balance regulates epithelial invasiveness and tumorigenesis[J]. Lab Invest, 2014, 94(10):1134-1146.
DOI
PMID
|
[15] |
ZHANG P, RUAN Y, XIAO J, et al. Association of serum follistatin levels with histological types and progression of tumor in human lung cancer[J]. Cancer Cell Int, 2018, 18:162.
DOI
PMID
|